Month: April 2017

New Health Canada Licences: Quantum Blue® Infliximab Assay, IBDoc®,CALEX® Cap

BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that three of its novel products, Quantum Blue® Infliximab Assay, IBDoc® and CALEX®Cap have received Medical Device Licences from Health Canada and are now commercially available in Canada. Quantum Blue® Infliximab® and CALEX® CAP devices were approved as Class II medical
Continue Reading

BUHLMANN Highlights: GanglioCombi™ MAG ELISA

BÜHLMANN GanglioCombi™ MAG ELISA is for Research Use Only. Not for use in diagnostic procedures. DOWNLOAD WHITE PAPER BÜHLMANN GanglioCombi™ MAG ELISA Comprehensive assay for anti-MAG and most prevalent anti-Ganglioside antibodies: (GM1, GM2, GD1a, GD1b, and GQ1b). The Neuroimmunology product line by BÜHLMANN is a list of robust assays for simple, esoteric testing for important
Continue Reading

The Value of Calprotectin in Inflammatory Bowel Disease Monitoring

Calprotectin: The Key to a Successful Treatment Pathway for IBD What is Inflammatory Bowel Disease? Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as  can be seen in many chronic diseases. IBD includes several different diseases; the two most
Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,